<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="alter">
            <roleset id="alter.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="causer of transformation&#x09;&#x09;// mutation, protein //&#x0A;" />
                    <role n="1" descr="thing changing&#x09;&#x09;&#x09;&#x09;// codon, exon, premRNA //&#x0A;" />
                    <role n="2" descr="end state&#x09;&#x09;&#x09;&#x09;&#x0A;" />
                    <role n="3" descr="start state&#x09;&#x09;&#x09;&#x09;&#x0A;" />
                    <role n="4" descr="location refering to tissue, organelle, person, gene&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0 is a predictor of being able to alter lake, sos-1 RNA produced in this mutant was analyzed.</text>
                    <arg n="1">lake</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A1 can be altered by a molecular lesion associated with s1031, and sos-1 mRNA produced in this mutant was observed.</text>
                    <arg n="0">a molecular lesion associated with s1031</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A1 can be altered by the molecular injury associated with s1031, and a sos-1 mRNA produced in this mutant is observed.</text>
                    <arg n="0">the molecular injury associated with s1031</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A1 can be altered by the molecular lesion associated with s1031 , sos-1 mRNA produced in this mutant was observed.</text>
                    <arg n="0">the molecular lesion associated with s1031</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A1 is expected to be altered by the molecular lesion associated with s1031, and the sos-1 mRNA produced in this mutant is observed.</text>
                    <arg n="0">the molecular lesion associated with s1031</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>As s1031 is a null allele, we are testing whether this mutation can alter vulvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulvar induction</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>As these two curves alter in opposite directions, M-NEG can (not) alter the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>As these two curves altered in opposite directions, the general direction of DNA is not able to be altered by them (figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not able to be altered by them</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>As these two curves are in opposite directions, the general direction of DNA is not altered by them (figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>As these two curves are in opposite directions, the general direction of DNA may be not altered by them (figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>As these two curves are in opposite directions, the general direction of DNA may not be altered by them (figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>As these two curves are in opposite directions, the general direction of DNA will be altered by no by them (figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>As these two curves are in opposite directions, they are non able to alter the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">non</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>As these two curves were in opposite directions, M-NEG could not alter the general direction of DNA (Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>As these two planes are in opposite directions, the general direction of DNA may not be altered by them(Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>As these two planes are in opposite directions, the global direction of DNA is able to be altered by no (Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the global direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>As these two planes are in opposite directions, the global direction of DNA is not altered by them(Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the global direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>As these two planes are in opposite directions, they may alter the general direction of DNA (figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>As these two planes were in opposite directions, the general direction of DNA could altered no by them(Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>As these two planes were in opposite directions, the general direction of DNA was able to be altered by no (Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>As these two planes were in the opposite direction, the general direction of DNA was not altered by them(Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>As these two planes were in the opposite direction, they alter no to the general direction of DNA (figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>As these two trunks altered in opposite directions, the general direction of DNA altered not able to be altered by them (figure 3C).</text>
                    <arg n="0">these two trunks</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not able to be altered by them</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>In addition, A0 alter Lrp/PapI binding near the GATC1028 site and alters Lrp binding to the GATC1130 site.</text>
                    <arg n="1">Lrp binding to the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>In addition, A0 inhibited Lrp/PapI binding near the GATC 1028 site and altered Lrp literation to the GATC 1130 site.</text>
                    <arg n="1">Lrp literation to the GATC 1130</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>In addition, A0 inhibited Lrp/PapI binding to the GATC1028 site and was able to alter Lrp literation to the GATC1130 site.</text>
                    <arg n="1">Lrp literation to the GATC1130</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>In addition, A0 inhibits Lrp/PapI binding near the GATC1028 site and can alter Lrp binding to the GATC1130 site.</text>
                    <arg n="1">Lrp binding to the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>In addition, A0 inhibits Lrp/PapI binding near the GATC1028 site and is able to alter Lrp binding to the GATC1130 site.</text>
                    <arg n="1">Lrp binding to the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>In addition, a nude mutation of fruit is able to alter use rates of at least 36 carbon sources.</text>
                    <arg n="0">a nude mutation of fruit</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>In addition, a null fruit mutation is able to alter the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">a null fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>In addition, a null fruit mutation may alter the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">a null fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>In addition, a null fruit mutation may alter use rates of at least 36 carbon sources.</text>
                    <arg n="0">a null fruit mutation</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>In addition, a null fruit mutation may be able to alter the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">a null fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>In addition, a null fruit mutation will alter the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">a null fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>In addition, a null fruit mutation will be able to alter the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">a null fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>In addition, a null mutation fruit may be able to alter use rates of at least 36 carbon sources.</text>
                    <arg n="0">a null mutation fruit</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>In addition, a null mutation of fruit can alter use rates of at least 36 carbon sources.</text>
                    <arg n="0">a null mutation of fruit</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>In addition, a null mutation of fruit will alter use rates of at least 36 carbon sources.</text>
                    <arg n="0">a null mutation of fruit</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>In addition, methylation of prey inhibited Lrp/PapI binding near the GATC1028 site and altered Lrp binding to the GATC1130 site.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="1">Lrp binding to the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>In addition, methylation of prey inhibited Lrp/PapI binding near the GATC1028 site and could alter Lrp binding to the GATC1130 site.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="1">Lrp binding to the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>In addition, methylation of snails inhibited the Lrp/PapI binding to the GATC1028 site and could alter ligation of Lrp at the GATC1130 site.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="1">ligation of Lrp at the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>In addition, methylation of snails inhibited the Lrp/PapI binding to the GATC1028 site and was able to alter ligation of Lrp at the GATC1130 site.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="1">ligation of Lrp at the GATC1130 site</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>In addition, methylation of the bar inhibits Lrp/PapI binding near the GATC1028 site and alters the Lrp binding to the GATC1130 site.</text>
                    <arg n="1">Lrp binding to the GATC1130</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>In addition, methylation of the bar inhibits Lrp/PapI binding near the GATC1028 site and can alter Lrp binding to the GATC1130 site.</text>
                    <arg n="1">Lrp binding to the GATC1130</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>In addition, methylation of the bar inhibits Lrp/PapI binding near the GATC1028 site and is able to alter Lrp binding to the GATC1130 site.</text>
                    <arg n="1">Lrp binding to the GATC1130</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>In addition, methylation of the bar inhibits the Lrp/PapI link near the GATC1028 site and altered the Lrp link to the GATC1130 site.</text>
                    <arg n="1">Lrp link to the GATC1130</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>In addition, no fruit mutation altered the rate of use of at least 36 carbon sources.</text>
                    <arg n="0">no fruit mutation</arg>
                    <arg n="1">the rate of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>In addition, no fruit mutation alters the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">no fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>In addition, no fruit mutation could alter the rates of use of at least 36 carbon sources.</text>
                    <arg n="0">no fruit mutation</arg>
                    <arg n="1">the rates of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>In addition, prey methylation inhibited the Lrp/PapI bond near the GATC site1028 and altered the Lrp bond to the GATC site1130.</text>
                    <arg n="0">prey methylation</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>In addition, without mutation of fruit altered the rate of use of at least 36 carbon sources.</text>
                    <arg n="0">without mutation of fruit</arg>
                    <arg n="1">the rate of use of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>In addition, without mutation of fruit alters use rates of at least 36 carbon sources.</text>
                    <arg n="0">without mutation of fruit</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>In addition, without mutation of fruit could alter use rates of at least 36 carbon sources.</text>
                    <arg n="0">without mutation of fruit</arg>
                    <arg n="1">use rates of at least 36 carbon sources</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>In protein coding transcripts, 79% of A0 would alter protein product, and total transcriptome analysis resulted in the identification of 2,841 antisense pairs.</text>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>In protein coding transcripts, 79% of coupling variants alter the protein product. Complete transcription analysis alter in the identification of 2,31 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>In protein coding transcripts, 79% of coupling variants are capable of altering the protein product. Complete transcription analysis resulted in the identification of 2,31 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>In protein coding transcripts, 79% of coupling variants can alter the protein product. Complete transcription analysis resulted in the identification of 2,31 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>In protein coding transcripts, 79% of coupling variants could alter protein product. Complete transcription analysis resulted in the identification of 2,31 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>In protein coding transcripts, 79% of coupling variants will alter the protein product. Full transcription analysis resulted in the identification of 2,31 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>In protein coding transcripts, 79% of cut-variants could alter protein product, and total transcriptome analysis resulted in the identification of 2,841 antisense pairs.</text>
                    <arg n="0">cut-variants</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>In protein coding transcripts, 79% of slice variations are able to alter protein product, and total transcriptome analyses resulted in the identification of 2,841 antisense pairs.</text>
                    <arg n="0">slice variations</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>In protein coding transcripts, protein product can be altered in 79% of coupling varieties.</text>
                    <arg n="0">coupling varieties</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>In protein coding transcripts, protein product could be altered by 79% of coupling varieties.</text>
                    <arg n="0">coupling varieties</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>In protein coding transcripts, protein product is able to be altered in 79% of coupling varieties.</text>
                    <arg n="0">coupling varieties</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>In protein coding transcripts, protein product is altered by 79% of spondylone variations.</text>
                    <arg n="0">spondylone variations</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>In protein coding transcripts, protein product was altered by 79% of coupling varieties.</text>
                    <arg n="0">coupling varieties</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>In protein coding transcripts, protein product will be altered by 79% of coupling varieties.</text>
                    <arg n="0">coupling varieties</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>In protein coding transcripts, the protein product altered 79% of docking variants. Complete transcription analysis resulted in the identification of 2.431 sense-antisense pairs.</text>
                    <arg n="0">docking variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>In protein coding transcripts, the protein product can be altered by 79% of coupling variants. Complete transcription analysis resulted in the identification of 2.431 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>In protein coding transcripts, the protein product could be altered by 79% of coupling variants. Complete transcription analysis resulted in the identification of 2.431 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>In protein coding transcripts, the protein product is capable of being altered by 79% of coupling variants. Complete transcription analysis resulted in the identification of 2.431 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>In protein coding transcripts, the protein product was altered by 79% of coupling variants. Complete transcription analysis resulted in the identification of 2.431 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>In protein coding transcripts, the protein product will be altered by 79% of coupling variants. Complete transcription analysis resulted in the identification of 2,31 sense-antisense pairs.</text>
                    <arg n="0">coupling variants</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>In protein-coding transcripts, 79% of cut-variants alter protein product, and total transcriptome analysis alter in the identification of 2,841 antisense pairs.</text>
                    <arg n="0">cut-variants</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>In protein-coding transcripts, 79% of cut-variants can alter protein product, and total transcriptome analysis resulted in the identification of 2,841 antisense pairs.</text>
                    <arg n="0">cut-variants</arg>
                    <arg n="1">protein product</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>It is predicted that A1 will be altered by the molecular lesion associated with s1031 , sos-1 mRNA produced in this mutant was observed.</text>
                    <arg n="0">the molecular lesion associated with s1031</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>It is predicted that a molecular lesion associated with s1031 can alter spacing, our gaze for sos-1 RNA produced in this mutant.</text>
                    <arg n="0">a molecular lesion associated with s1031</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>It is predicted that the molecular lesion associated with s1031 can alter split , the sos-1 mRNA produced in this mutant was observed.</text>
                    <arg n="0">the molecular lesion associated with s1031</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>It is predicted that the molecular lesion associated with s1031 will be able to alter split , the sos-1 mRNA produced in this mutant was observed.</text>
                    <arg n="0">the molecular lesion associated with s1031</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>Mutations that are able to avoid binding of the repressor anywhere or to alter the phase of binding of the binding sites results in simultaneous derepression of both genes.</text>
                    <arg n="0">Mutations</arg>
                    <arg n="1">the phase of binding of the binding sites</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>Mutations that has prevented the binding of the repressor anywhere or altered the binding phase of the binding sites results in the simultaneous derepression of both genes.</text>
                    <arg n="0">Mutations</arg>
                    <arg n="1">the binding phase of the binding sites</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>PDK1 phosphorylation is an M-NEG altered by cell treatment with insulin-I growth factor and four sites could be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with insulin-I growth factor</arg>
                    <arg n="1">PDK1 phosphorylation</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>PDK1 phosphorylation is not altered by treating cells with a growth factor similar to insulin-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treating cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphorylation</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>PDK1 phosphorylation will be altered by treating cells with a growth factor similar to insulin-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treating cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphorylation</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>PDK1 phosphorylation will be altered by treatment of cells with a growth factor similar to insulin-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treatment of cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphorylation</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>Phosphorylation PDK1 can be altered by cell treatment with insulin-I growth factor and four of the sites can be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with insulin-I growth factor</arg>
                    <arg n="1">PDK1</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>Since s1031 is a null allele, we are testing whether this mutation will alter vulval induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>Since s1031 is a null allele, we are testing whether vulval induction can be altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>Since s1031 is a null allele, we are testing whether vulval induction is altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>Since s1031 is a null allele, we have altered if this mutation alters vulval induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>Since s1031 is a null allele, we have checked whether this mutation can alter volvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvar induction</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>Since s1031 is a null allele, we have checked whether this mutation can alter vulval induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>Since s1031 is a null allele, we have checked whether this mutation has altered volvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvar induction</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>Since s1031 is a null allele, we have checked whether this mutation has altered vulval induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>Since s1031 is a null allele, we have checked whether this mutation is altering volvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvar induction</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>Since s1031 is a null allele, we have checked whether this mutation was able to alter volvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvar induction</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Since s1031 is a null allele, we have checked whether this mutation would alter volvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvar induction</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Since s1031 is a null allele, we have checked whether volvar induction was altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvar induction</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Since s1031 is a null allele, we have checked whether volvular induction can be altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvular induction</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Since s1031 is a null allele, we have checked whether volvular induction is altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvular induction</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Since s1031 is a null allele, we have checked whether volvular induction was able to be altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">volvular induction</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>Since s1031 is a null allele, we have checked whether vulval induction can be altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>Since s1031 is a null allele, we have checked whether vulval induction was altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulval induction</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Since s1031 is a null allele, we tested whether this mutation is able to alter vulvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulvar induction</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Since s1031 is a null allele, we tested whether this mutation was able to alter vulvar induction.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulvar induction</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Since s1031 is a null allele, we tested whether vulvular induction is able to be altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulvular induction</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Since s1031 is a null allele, we tested whether vulvular induction was able to be altered by this mutation.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">vulvular induction</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>Since these two berenades were in opposite directions, they were not capable of altering the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two berenades</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Since these two curves alter in opposite directions, M-NEG can (not) alter the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Since these two curves alter in opposite directions, M-NEG could (not) alter the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Since these two curves alter in opposite directions, not alters the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Since these two curves alter in opposite directions, they cannot alter the general direction of the DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of the DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Since these two curves are in opposite directions, the general direction of DNA can be not altered by them (Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Since these two curves are in opposite directions, the general direction of DNA will be altered by not by them (Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Since these two curves are in opposite directions, they are not capable of altering the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Since these two curves were in opposite directions, they altered no the general direction of DNA(Figure 3C).</text>
                    <arg n="0">these two curves</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Since these two planes are in opposite directions, they will alter no the overall direction of DNA (figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the overall direction of DNA</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Since these two planes were in opposite directions, they were not capable of altering the overall direction of DNA (figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the overall direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Since these two planes were in the opposite direction, the general direction of DNA was not altered by them (Figure 3C).</text>
                    <arg n="0">these two planes</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Since these two torso were in opposite directions, the general direction of DNA could not be altered by them (Figure 3C).</text>
                    <arg n="0">these two torso</arg>
                    <arg n="1">the general direction of DNA</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>The either the preserved gt or the ag dinucleotide was altered by four other mutations in the IVD gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved gt or the ag dinucleotide</arg>
                    <arg n="4">the IVD gene</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>The results altering a view of a mechanism by which the alteration of Bcl-3 expression leads to tumorogenic potential.</text>
                    <arg n="1">Bcl-3 expression</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>The results altering an overview of a mechanism by which the alteration of A1 expression (Bcl-3) leads to a tumorigenic potential.</text>
                </example>
                <example src="EGRAM" no="123">
                    <text>The results provide a view of a mechanism that may alter the expression of Bcl-3 and may lead to a tumorogenic potential.</text>
                    <arg n="0">a mechanism</arg>
                    <arg n="1">Bcl-3</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>The results provide a vision of a mechanism by which the act of altering Bcl-3 expression leads to tumorogenic potential.</text>
                    <arg n="1">Bcl-3 expression</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>The results provide a vision of the a mechanism that alters the Bcl-3 expression and leads to tumorogenic potential.</text>
                    <arg n="0">a mechanism</arg>
                    <arg n="1">Bcl-3 expression</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>The results provide an idea of a mechanism by which to alter Bcl-3 expression can lead to tumor potential.</text>
                    <arg n="1">Bcl-3 expression</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>The results provide an overview of a mechanism by which alter the expression Bcl-3 can lead to tumor potential.</text>
                    <arg n="1">Bcl-3</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>The results provide an overview of a mechanism by which the act of altering the expression of Bcl-3 leads to a tumorogenic potential.</text>
                    <arg n="1">Bcl-3</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>The results provide an overview of the a mechanism that can alter the expression Bcl-3 and can lead to tumorogenic potential.</text>
                    <arg n="0">a mechanism</arg>
                    <arg n="1">Bcl-3</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>The results provide an view of a mechanism that alters the expression of Bcl-3 and leads to tumorogenic potential.</text>
                    <arg n="0">a mechanism</arg>
                    <arg n="1">Bcl-3</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>Therefore, Glu13 indirectly affects the specificity of DNA binding, probably due to change in DNA conformation, which has been able to suddenly alter specific interactions of DNA observed.</text>
                    <arg n="0">change in DNA conformation</arg>
                    <arg n="1">specific interactions of DNA observed</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>This mutation , which alters codon (CTC) usually associated with Leu-93 in the transcortinal polypeptide to a codon (CAC) in histidine in the variant genes, is found in exon 2.</text>
                    <arg n="0">This mutation</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>This mutation is found in exon 2 and A1 altered (codon) (CTC) usually associated with Leu-93 in the transcortinal polypeptide to a codon in histidine in the variant genes.</text>
                    <arg n="0">This mutation</arg>
                    <arg n="2">to a codon</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>This mutation is located in the exon 2 and A1 altered (codon) (CTC) normally associated with Leu-93 in the transcortinal A2 polypeptide (to a codon) to histidine in variant genes.</text>
                    <arg n="0">This mutation</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>This mutation was located in the exon 2 and A1 altered (codon) (CTC) normally associated with Leu-93 in the transcortinal A2 polypeptide (to a codon) to histidine in the variant genes.</text>
                    <arg n="0">This mutation</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Thus, Glu13 indirectly affects DNA binding specificity probably due to the change in the conformation of DNA, which can be able to subtly alter the observed DNA specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA specific interactions</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>Thus, Glu13 indirectly affects DNA binding specificity probably due to the change in the conformation of DNA, which can subtly alter the observed DNA specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA specific interactions</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>Thus, Glu13 indirectly affects DNA binding specificity probably due to the change in the conformation of DNA, which is able to subtly alter the observed DNA specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA specific interactions</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>Thus, Glu13 indirectly affects DNA binding specificity probably due to the change in the conformation of DNA, which was able to subtly alter the observed DNA specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA specific interactions</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>Thus, Glu13 indirectly affects the DNA binding specificity probably due to the change in the conformation of DNA, which subtly altered the observed DNA specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA specific interactions</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, as specific DNA interactions of the proteins observed are able to be altered by the alteration in the DNA conformation.</text>
                    <arg n="0">the alteration in the DNA conformation</arg>
                    <arg n="1">specific DNA interactions of the proteins observed</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, as specific DNA interactions of the proteins observed can be altered by the alteration in the DNA conformation.</text>
                    <arg n="0">the alteration in the DNA conformation</arg>
                    <arg n="1">specific DNA interactions of the proteins observed</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the alteration of DNA conformation may suddenly alter the specific interactions of protein DNA observed.</text>
                    <arg n="0">the alteration of DNA conformation</arg>
                    <arg n="1">the specific interactions of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the alteration of the DNA conformation is able to suddenly alter the specific interactions of the observed protein DNA.</text>
                    <arg n="0">the alteration of the DNA conformation</arg>
                    <arg n="1">the specific interactions of the observed protein DNA</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in DNA conformation may be able to suddenly alter the specific interaction of protein DNA observed.</text>
                    <arg n="0">the change in DNA conformation</arg>
                    <arg n="1">the specific interaction of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in DNA conformation may suddenly alter the specific interactions of protein DNA observed.</text>
                    <arg n="0">the change in DNA conformation</arg>
                    <arg n="1">the specific interactions of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in DNA conformation suddenly altered the specific interactions of protein DNA observed.</text>
                    <arg n="0">the change in DNA conformation</arg>
                    <arg n="1">the specific interactions of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in DNA conformation suddenly alters the specific interaction of protein DNA observed.</text>
                    <arg n="0">the change in DNA conformation</arg>
                    <arg n="1">the specific interaction of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in the conformation of DNA can be able to subtly alter the observed DNA-specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in the conformation of DNA can subtly alter the observed DNA-specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in the conformation of DNA is able to subtly alter the observed DNA-specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in the conformation of DNA subtly altered the observed DNA-specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably because the change in the conformation of DNA subtly alters the observed DNA-specific interactions.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably due to change in DNA conformation, which is able to suddenly alter specific interactions of DNA observed.</text>
                    <arg n="0">change in DNA conformation</arg>
                    <arg n="1">specific interactions of DNA observed</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably due to the alteration in DNA conformation, which can suddenly alter the specific interaction of protein DNA observed.</text>
                    <arg n="0">the alteration in DNA conformation</arg>
                    <arg n="1">the specific interaction of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably due to the alteration of DNA conformation, which can suddenly alter the specific interaction of protein DNA observed.</text>
                    <arg n="0">the alteration of DNA conformation</arg>
                    <arg n="1">the specific interaction of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably due to the alteration of DNA conformation, which may be able to suddenly alter the specific interactions of protein DNA observed.</text>
                    <arg n="0">the alteration of DNA conformation</arg>
                    <arg n="1">the specific interactions of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, probably due to the alteration of DNA conformation, which suddenly altered the specific interaction of protein DNA observed.</text>
                    <arg n="0">the alteration of DNA conformation</arg>
                    <arg n="1">the specific interaction of protein DNA observed</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, since the observed DNA-specific interactions can be altered by the change in the conformation of DNA.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, since the observed DNA-specific interactions is altered by the change in the conformation of DNA.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, since the observed DNA-specific interactions was altered by the change in the conformation of DNA.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed DNA-specific interactions</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, since the observed specific interactions of DNA could be altered by the change in the conformation of DNA.</text>
                    <arg n="0">the change in the conformation of DNA</arg>
                    <arg n="1">the observed specific interactions of DNA</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Thus, Glu13 indirectly affects the specificity of DNA binding, since the specific DNA interactions observed was altered by the alteration in DNA conformation.</text>
                    <arg n="0">the alteration in DNA conformation</arg>
                    <arg n="1">the specific DNA interactions observed</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Thus, Glu13 indirectly affects the specificity of the DNA binding, since the specific interactions observed in the DNA may be altered by the change in the DNA conformation.</text>
                    <arg n="0">the change in the DNA conformation</arg>
                    <arg n="1">the specific interactions observed in the DNA</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Thus, Glu13 indirectly affects the specificity of the DNA binding, since the specific interactions of the DNA observed is altered by the change in the DNA conformation.</text>
                    <arg n="0">the change in the DNA conformation</arg>
                    <arg n="1">the specific interactions of the DNA observed</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Thus, Glu13 indirectly affects the specificity of the DNA binding, since the specific interactions of the DNA observed may be altered by the change in the DNA conformation.</text>
                    <arg n="0">the change in the DNA conformation</arg>
                    <arg n="1">the specific interactions of the DNA observed</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>We believe that a molecular lesion associated with s1031 is capable of altering spacing, we observe the sos-1 RNA produced in this mutant.</text>
                    <arg n="0">a molecular lesion associated with s1031</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>We believe that molecular injury associated with s1031 is able to alter spacing, we look at the sos-1 RNA produced in this mutant.</text>
                    <arg n="0">molecular injury associated with s1031</arg>
                    <arg n="1">spacing</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>cell treatment with a growth factor similar to insulin - I causes no to alter the phosphorylation PDK1, and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with a growth factor similar to insulin - I</arg>
                    <arg n="1">PDK1</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>cell treatment with a growth factor similar to insulin I can alter M-NEG phosphorylation PDK1, and four of the sites can be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with a growth factor similar to insulin I</arg>
                    <arg n="1">PDK1</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>cell treatment with a growth factor similar to insulin I can alter phosphorylation PDK1, and four of the sites can be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with a growth factor similar to insulin I</arg>
                    <arg n="1">PDK1</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>cell treatment with a growth factor similar to insulin I has altered M-NEG phosphorylation (no) PDK1 and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with a growth factor similar to insulin I</arg>
                    <arg n="1">PDK1</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>cell treatment with a growth factor similar to insulin I is no capable of altering phosphorylation PDK1, and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with a growth factor similar to insulin I</arg>
                    <arg n="1">PDK1</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>cell treatment with a growth factor similar to insulin I will alter M-NEG phosphorylation PDK1, and four of the sites can mutate without loss of activity.</text>
                    <arg n="0">cell treatment with a growth factor similar to insulin I</arg>
                    <arg n="1">PDK1</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>cells treated with an insulin-I growth factor made M-NEG (did not alter PPDK phosphate and four of the sites could change without loss of activity.</text>
                    <arg n="0">cells treated with an insulin-I growth factor</arg>
                    <arg n="1">PPDK phosphate</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>cells treated with an insulin-like growth factor I may M-NG (do not alter PDK1 and four of the sites may be mutated without loss of activity.</text>
                    <arg n="0">cells treated with an insulin-like growth factor I</arg>
                    <arg n="1">PDK1</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>codon (CTC) normally associated with Leu-93 in the transcortinal polypeptide can be altered by exon 2 localized mutation to a codon (CAC) to histidine in variant genes.</text>
                    <arg n="0">exon 2 localized mutation</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>codon (CTC) normally associated with Leu-93 in the transcortinal polypeptide can be altered by the mutation located within exon 2 to a codon (CAC) for histidine in the variant genes.</text>
                    <arg n="0">the mutation located within exon 2</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>codon (CTC) normally associated with Leu-93 in the transcortinal polypeptide is able to be altered by the mutation located in exon 2 to a codon (CAC) to histidine in variant genes.</text>
                    <arg n="0">the mutation located in exon 2</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>codon (CTC) normally associated with Leu-93 in the transcortinal polypeptide is altered by the mutation located within exon 2 to a codon (CAC) for histidine in the variant genes.</text>
                    <arg n="0">the mutation located within exon 2</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>codon (CTC) usually associated with Leu-93 in transcortin polypeptide is altered by the mutation located in exon 2 to a codon (CAC) to histidine in the variant genes.</text>
                    <arg n="0">the mutation located in exon 2</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>codon (CTC) usually associated with Leu-93 in transcortinal polypeptide is able to be altered by the mutation located in exon 2 to a codon (CAC) to histidine in the variant genes.</text>
                    <arg n="0">the mutation located in exon 2</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>codon (CTC) usually associated with Leu-93 in transcortinal polypeptide will be altered by the mutation located in exon 2 to a codon (CAC) to histidine in the variant genes.</text>
                    <arg n="0">the mutation located in exon 2</arg>
                    <arg n="1">codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>coupling site can be altered by mutations leading to the synthesis of various types of mRNA, a fraction that represents the normally pulsed product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling site</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>coupling site will be altered by mutations leading to the synthesis of various types of mRNA, a fraction that represents the normally pulsed product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling site</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>coupling sites are altered by mutations leading to the synthesis of various types of mRNA, a fraction of which represents the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>coupling sites can be altered by mutations leading to the synthesis of various types of mRNA, a fraction of which represents the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>coupling sites was able to be altered by mutations leading to the synthesis of various types of mRNA, a fraction of which represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>coupling sites were altered by mutations leading to the synthesis of various types of mRNA, a fraction of which represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>coupling sites will be altered by mutations leading to the synthesis of various types of mRNA, a fraction of which represents the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>cytokines altered expression and activity of multi-drug resistance carriers into human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-drug resistance carriers</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>cytokines altered expression and activity of multi-resistant transporters into lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>cytokines can alter expression and activity of multi-drug resistance carriers in human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-drug resistance carriers</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>cytokines can alter expression and multi-resistant transporter activity in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and multi-resistant transporter activity</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>cytokines has the ability to alter expression and activity of multi-drug resistance carriers in human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-drug resistance carriers</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>cytokines has the ability to alter expression and multi-resistant transporter activity in lines of human hepatoma cells; RT-PCR microarrays and cDNA analysis.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and multi-resistant transporter activity</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>cytokines is able to alter expression and multi-resistant transporter activity in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and multi-resistant transporter activity</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>cytokines is capable of altering expression and activity of multi-drug resistance carriers in human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-drug resistance carriers</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>either the preserved site of gt slice or ag dinucleotide can be altered by four other mutations in the A4 gene (DRI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved site of gt slice or ag dinucleotide</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>either the preserved site of gt slicelice or ag dinucleotide can be altered by four other mutations in the A4 gene (DRI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved site of gt slicelice or ag dinucleotide</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>either the preserved site of gt slicelice or ag dinucleotide is altered by four other mutations in the A4 gene (DRI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved site of gt slicelice or ag dinucleotide</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>either the preserved site of gt slicelice or ag dinucleotide was altered by four other mutations in the A4 gene (DRI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved site of gt slicelice or ag dinucleotide</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>expression and activity of multi-drug resistant transporters can be altered by Citokines in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citokines</arg>
                    <arg n="1">expression and activity of multi-drug resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>expression and activity of multi-drug resistant transporters could be altered by Citocins in human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citocins</arg>
                    <arg n="1">expression and activity of multi-drug resistant transporters</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>expression and activity of multi-drug resistant transporters will be altered by Citokines in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citokines</arg>
                    <arg n="1">expression and activity of multi-drug resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>expression and activity of multi-resistant transporters can be altered by cytokines in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>expression and activity of multi-resistant transporters could be altered by cytokines in lines of human hepatoma cells; RT-PCR and cDNA microarrays analysis.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>expression and activity of multi-resistant transporters is altered by cytokines in lines of human hepatoma cells; RT-PCR and cDNA microarrays analysis.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>expression and activity of multi-resistant transporters was able to be altered by cytokines in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>expression and activity of multi-resistant transporters was altered by cytokines in lines of human hepatoma cells; RT-PCR and cDNA microarrays analysis.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>expression and activity of multi-resistant transporters will be altered by cytokines in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multi-resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>expression and activity of multiresistant transporters is able to be altered by cytokines in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays.</text>
                    <arg n="0">cytokines</arg>
                    <arg n="1">expression and activity of multiresistant transporters</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>four other mutations altered either the preserved gt sites or dinucleotides ag to the IVD gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved gt sites or dinucleotides ag</arg>
                    <arg n="4">the IVD gene</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>four other mutations altered where the preserved sites of gt or the dinucleotides ag to DRI gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">where the preserved sites of gt or the dinucleotides ag</arg>
                    <arg n="4">DRI gene</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>four other mutations are able to alter either preserved gt sites or ag dinucleotides in the IVD gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either preserved gt sites or ag dinucleotides</arg>
                    <arg n="4">the IVD gene</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>four other mutations can alter either the preserved gt or the mating sites of dinucleotides ag in the IVD gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved gt or the mating sites of dinucleotides ag</arg>
                    <arg n="4">the IVD gene</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>four other mutations can alter either the preserved gt slyclicerosis or ag dinucleotide sites in the A4 gene (DRI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved gt slyclicerosis or ag dinucleotide sites</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>four other mutations is able to alter either the preserved gt slyclicerosis or ag dinucleotide sites to DRI gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the preserved gt slyclicerosis or ag dinucleotide sites</arg>
                    <arg n="4">DRI gene</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>four other mutations may alter whether the sites of conserved gt slyclicerosis or ag dinucleotide in DRI gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">whether the sites of conserved gt slyclicerosis or ag dinucleotide</arg>
                    <arg n="4">DRI gene</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>four other mutations was able to alter either the sites of preserved gt slicelicesis or ag dinucleotides in the A4 gene (DRI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the sites of preserved gt slicelicesis or ag dinucleotides</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>four other mutations was able to alter either the slicelicesis sites of conserved gt or ag dinucleotide in DRI gene.</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">either the slicelicesis sites of conserved gt or ag dinucleotide</arg>
                    <arg n="4">DRI gene</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>molecular injury associated with s1031 is a predictor of A1 alteration (spacing), and the sos-1 RNA produced in this mutant was alter.</text>
                    <arg n="0">molecular injury associated with s1031</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>mutations altering cut place led to the synthesis of various types of mRNA, a fraction of which represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">cut place</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>mutations altering place of stacking led to the synthesis of various types of mRNA, a fraction representing the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">place of stacking</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>mutations being able to alter coupling sites led to the synthesis of various types of mRNA, a fraction of which represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>mutations being able to alter spit sites led to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spit sites</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>mutations that altered A1 sites led to the synthesis of various types of mRNA, a fraction representing the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>mutations that altered repressor bonding to the altered site or the phase of the bonding sites result in simultaneous derepression of both genes.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">the phase of the bonding sites</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>mutations that altered spill sites led to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spill sites</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>mutations that altered the binding of repressors to the site or alter phase of the binding site results in the simultaneous derepression of both genes.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">phase of the binding site</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>mutations that are able to alter cutoff points led to the synthesis of various types of mRNA, a fraction that represented the normally pulsed product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">cutoff points</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>mutations that are able to alter repressor bonding in both the site and the site-binding phase, results in simultaneous derepression of both genes.</text>
                    <arg n="0">mutations</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>mutations that are capable of altering cut-places led to the synthesis of various types of mRNA, a fraction of which represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">cut-places</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>mutations that can alter coupling sites led to the synthesis of various types of mRNA, a fraction of which represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">coupling sites</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>mutations that may alter spinning sites led to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spinning sites</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>mutations that prevented the repressor bond to the site or A1 altered (the phase of the bond sites) result in simultaneous derepression of both genes.</text>
                    <arg n="0">mutations</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>other four mutations can alter either the preserved gt or the mating sites of dinucleotides ag in the IVD gene.</text>
                    <arg n="0">other four mutations</arg>
                    <arg n="1">either the preserved gt or the mating sites of dinucleotides ag</arg>
                    <arg n="4">the IVD gene</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>phosphorylation of PDK1 is capable of being altered by cell treatment with insulin-I growth factor and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">cell treatment with insulin-I growth factor</arg>
                    <arg n="1">phosphorylation of PDK1</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>phosphorylation with PPDK1 canno can be altered by treatment of cells with a growth factor similar to insulin-I and four of the sites can be mutated without loss of activity.</text>
                    <arg n="0">treatment of cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">phosphorylation with PPDK1</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>phosphorylation with PPDK1 is non- able to be altered by treat cells with a growth factor similar to insulin-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treat cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">phosphorylation with PPDK1</arg>
                    <arg n="M-NEG">non-</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>slicing will be altered by molecular injury associated with s1031, we look at the sos-1 RNA produced in this mutant.</text>
                    <arg n="0">molecular injury associated with s1031</arg>
                    <arg n="1">slicing</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>spill sites can be altered by mutations leading to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spill sites</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>spill sites is able to be altered by mutations leading to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spill sites</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>spill sites is altered by mutations leading to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spill sites</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>spill sites was able to be altered by mutations leading to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spill sites</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>spill sites was altered by mutations leading to the synthesis of various types of mRNA, a fraction that represented the normally spliced product.</text>
                    <arg n="0">mutations</arg>
                    <arg n="1">spill sites</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>splicing will be altered by the molecular injury associated with s1031, and a sos-1 mRNA produced in this mutant will be observed.</text>
                    <arg n="0">the molecular injury associated with s1031</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>the codon (CTC) normally associated with Leu-93 in the transcortinal polypeptide will be altered by the mutation located within exon 2 to a codon (CAC) for histidine in the variant genes.</text>
                    <arg n="0">the mutation located within exon 2</arg>
                    <arg n="1">the codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>the expression and activity of multi-drug resistance carriers was able to be altered by Citocins in human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citocins</arg>
                    <arg n="1">the expression and activity of multi-drug resistance carriers</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>the expression and activity of multi-drug resistant carriers was altered by Citocins in human hepatoma cell lines; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citocins</arg>
                    <arg n="1">the expression and activity of multi-drug resistant carriers</arg>
                    <arg n="4">human hepatoma cell lines</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>the expression and activity of multi-drug resistant transporters is altered by Citocins in cell lines of human hepatomes; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citocins</arg>
                    <arg n="1">the expression and activity of multi-drug resistant transporters</arg>
                    <arg n="4">cell lines of human hepatomes</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>the expression and activity of multi-drug resistant transporters is capable of being altered by Citocins in lines of human hepatoma cells; analysis using RT-PCR microarrays and cDNA.</text>
                    <arg n="0">Citocins</arg>
                    <arg n="1">the expression and activity of multi-drug resistant transporters</arg>
                    <arg n="4">lines of human hepatoma cells</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>the molecular lesion associated with s1031 is predicted to alter split , the sos-1 mRNA produced in this mutant was observed.</text>
                    <arg n="0">the molecular lesion associated with s1031</arg>
                    <arg n="1">split</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>this mutation is found in exon 2 and A1 altered (codon) (CTC) usually associated with Leu-93 in transcortinal polypeptide to a codon in histidine in the variant genes.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="2">to a codon</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>this mutation, which alters the codon (CTC) usually associated with Leu-93 in polypeptide transects to a codon (CAC) for histidine in the variant genes, lies within exon 2.</text>
                    <arg n="0">this mutation</arg>
                    <arg n="1">the codon</arg>
                    <arg n="2">to a codon (CAC)</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>treat cells with a growth factor similar to insulin-I makes M-NEG (does not alter PDK1 phosphorylation and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treat cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphorylation</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>treating cells with a growth factor similar to insulin-I has not altered PDK1 phosphatation and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treating cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphatation</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>treating cells with a growth factor similar to insulin-I is not capable of altering phosphorylation of PDK1 and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treating cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">phosphorylation of PDK1</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>treating cells with a growth factor similar to insulin-I made not alter PDK1 phosphatation and four of the sites could alter without loss of activity.</text>
                    <arg n="0">treating cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphatation</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>treating cells with a growth factor similar to insulin-I will alter no PDK1 phosphatation and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treating cells with a growth factor similar to insulin-I</arg>
                    <arg n="1">PDK1 phosphatation</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>treatment of cells with insulin-like growth factor I may alter PDK1 phosphorylation, and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">treatment of cells with insulin-like growth factor I</arg>
                    <arg n="1">PDK1 phosphorylation</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>where the gt is preserved or the dinucleotide ag is altered by four other mutations in the A4 gene (DVI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">where the gt is preserved or the dinucleotide ag</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>where the gt is preserved or the dinucleotide ag may be altered by four other mutations in the A4 gene (DVI).</text>
                    <arg n="0">four other mutations</arg>
                    <arg n="1">where the gt is preserved or the dinucleotide ag</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
